Navigation Links
Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
Date:4/22/2010

HARBIN, China, April 22 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company has significantly reduced its Days Sales Outstanding ("DSO"), resulting in improved cash flow from operations and healthier working capital.

For fiscal year 2009, Renhuang reported Days Sales Outstanding of 185 days. At the end of first quarter of 2010, through a variety of management initiatives, the Company effectively reduced its DSO to 117 days. Renhuang's management expects to further lower the DSO period to 100 days by the second quarter, an improvement of over 15% compared with the first quarter and over 46% compared with fiscal year 2009. Management anticipates continued improvement in Days Sales Outstanding in the coming quarters.

The Company's growing sales have contributed to the improvement in DSO. In the past, Renhuang extended special credit terms to its sales agents in order to promote sales. These favorable terms often included lengthy payment periods, resulting in longer Days Sales Outstanding. With the Company's improved position within the pharmaceuticals industry, it is no longer necessary for Renhuang to extend such favorable credit terms and current arrangements have significantly compressed payment periods.

"We continue to focus on strengthening our balance sheet and financial condition, more importantly our accounts receivables. The effective reduction in our DSO, reflects Renhuang's ability to manage risk and demonstrates improvement in our sales management," commented Mr. Shaoming Li, the Chairman and CEO of Renhuang. "We are confident the improvement in DSO will positively impact our operating cash flow and working capital."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, visit http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward- looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to achieve its financial guidance, ability to continue to improve its days sales outstanding, ability to list its shares on a senior stock exchange, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For more information, please contact:

    Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Tel:   +86-451-5392-5461
     Email: ir@renhuang.com

    CCG Investor Relations:
     Ms. Lei Huang, Account Manager
     Phone:   +1-646-833-3417 (New York)
     Email:   lei.huang@ccgir.com
     Website: www.ccgirasia.com

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
2. Renhuang Announces Price Increase on Shengmai Granules
3. Renhuang Announces Fiscal Year 2010 Guidance
4. Celator(R) Pharmaceuticals Presents New Data on Two Nano-Scale Delivery Platforms at the American Association for Cancer Research
5. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
6. Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
7. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
8. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
10. Poniard Pharmaceuticals Announces $6.3 Million Financing
11. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
Breaking Medicine News(10 mins):